scPharmaceuticals

SCPH · NASDAQ

Price unavailable right now.

No price history for this range.

SCPH analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated May 1, 2025

Bull case

scPharmaceuticals Inc. has demonstrated impressive sales growth, with a 24.5% increase in Furoscix product sales from the previous quarter, and a significant jump in total product revenue to $10.0M, up from $3.8M year-over-year. The company also reported a notable improvement in gross-to-net revenue, which increased to 15.7% in the third quarter, compared to 8% in the previous quarter, further indicating enhanced pricing power following a 5.5% price increase for Furoscix. Furthermore, demand for Furoscix remains strong, with a 23% growth in doses delivered in the fourth quarter, demonstrating robust market interest and potential for further revenue increases as interactions with healthcare providers expand.

Bear case

scPharmaceuticals's latest quarterly sales of $10 million for Furoscix represented a 24% year-over-year growth but fell short of both internal estimates and consensus expectations, indicating potential challenges in meeting market demands. The company's loss per share of $0.75 exceeded both internal and market forecasts, adding pressure on its financial outlook. Furthermore, due to concerns of patient frustration over high copays and a conservative adjustment to fiscal year revenue estimates, scPharmaceuticals's outlook appears increasingly cautious amid shifting focus towards off-the-shelf delivery technologies.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.